Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

The neffyinSchools program from ARS Pharma will provide eligible public and private K-12 schools in the United States with ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

Compared with placebo, zavegepant nasal spray yielded sustained relief of acute pain and function in migraine.

Milestone’s NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...

Milestone Pharmaceuticals (MIST) announced that it has received Notice of Allowance from the United States Patent and Trademark Office, or ...

Researchers at Texas A&M University College of Medicine have developed a new therapy that may slow the progression of ...

Letters to the editors for the November 2024 issue of Scientific American ...

A Massachusetts man is the only one in the country who has tried a nasal spray treatment for Alzheimer's. He's going to help ...

Almost 100,000 bottles of nasal spray were recalled for a "microbial failure" that led to multiple complaints from customers.

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.